Ratings Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Real-time Estimate Cboe BZX Other stock markets 02:39:49 2024-05-29 pm EDT			5-day change	1st Jan Change
10.12 ^USD	-1.65%		-1.74%	+11.39%

May. 09	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PHATHOM PHARMACEUTICALS, INC.	+11.39%	602M	C-
MODERNA, INC.	+46.80%	58.71B	B-
IQVIA HOLDINGS INC.	-3.58%	41.31B	B
LONZA GROUP AG	+36.42%	39.2B	A
CELLTRION, INC.	-11.22%	27.4B	C
ICON PUBLIC LIMITED COMPANY	+9.29%	26.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.98B	B
BIO-TECHNE CORPORATION	+1.52%	12.51B	B+
MEDPACE HOLDINGS, INC.	+24.49%	12.08B	C+
UNITED THERAPEUTICS CORPORATION	+21.97%	11.94B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes